title: Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative).
abstract: Since the introduction of drug-eluting stents (DESs), patterns of revascularization strategies for patients with non-ST-segment elevation acute coronary syndromes have not been assessed. We studied 82,924 patients from the CRUSADE Initiative who presented with non-ST-segment elevation acute coronary syndromes and underwent coronary angiography at 365 United States hospitals that had capabilities for surgical (coronary artery bypass grafting [CABG]) and percutaneous (percutaneous coronary intervention [PCI]) revascularization from January 2002 to June 2005. Temporal trends in the use of PCI, CABG, and medical management without revascularization were analyzed with respect to the introduction of DESs. In total, 73,577 patients (89%) had >50% stenosis in > or =1 coronary artery, and there was a significant increase in the use of PCI (vs CABG or medical management without revascularization) during the study period (38.3% vs 52.5%). By quarter 2 of 2005, 80% of patients who underwent PCI received a DES. In total, 18,462 of 25,068 patients (73.6%) with 3-vessel disease (3VD) underwent revascularization and use of CABG decreased for these patients (48.9% to 39.9%, p <0.001), whereas use of PCI increased (51.1% to 60.1%, p <0.001). Factors significantly associated with use of PCI for patients with 3VD who underwent any revascularization included previous PCI, previous CABG, cardiology inpatient care, care at an academic hospital, renal insufficiency, and previous congestive heart failure. In conclusion, coinciding with the introduction of DESs, there has been a significant increase in the use of PCI and, in those patients with 3VD, a decrease in the use of CABG with a shift toward increasing use of PCI. Long-term implications of this shift remain uncertain, especially in patients with 3VD.
authors.affiliation: University of Vermont College of Medicine, Burlington, Vermont, USA. prospero.gogo@vtmednet.org
authors.forename: Prospero B
authors.initials: PB
authors.lastname: Gogo
authors.forename: Harold L
authors.initials: HL
authors.lastname: Dauerman
authors.forename: Jyotsna
authors.initials: J
authors.lastname: Mulgund
authors.forename: E Magnus
authors.initials: EM
authors.lastname: Ohman
authors.forename: Manesh R
authors.initials: MR
authors.lastname: Patel
authors.forename: David J
authors.initials: DJ
authors.lastname: Cohen
authors.forename: Jorge F
authors.initials: JF
authors.lastname: Saucedo
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
authors.forename: W Brian
authors.initials: WB
authors.lastname: Gibler
authors.forename: Sidney C
authors.initials: SC
authors.lastname: Smith
authors.forename: Eric D
authors.initials: ED
authors.lastname: Peterson
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Roe
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data* / Q000639:trends*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data* / Q000639:trends*; D003327:Coronary Disease / Q000628:therapy*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D013577:Syndrome; D014481:United States
chemical_list: D002317:Cardiovascular Agents